



Dr Susana Vives

*Vilnius University Hospital Santaros Klinikos, Vilna,
 Lithuania*

Professional Qualifications:

Name of Granting Institution	Location (City, Country)	Degree	Obtained (Year)
Universitat Autònoma	Barcelona (Spain)	Physician	2002
H. Universitari Germans Trias i Pujol	Badalona (Barcelona, Spain)	Hematologist	2007
Universitat	Valencia (Spain)	Master's Degree in Hematopoietic Transplantation (on-line)	2016
Universitat Autònoma	Barcelona (Spain)	Doctoral Student	Ongoing

Cooperative Groups:

Active member of the CETLAM and PETHEMA Spanish Cooperative Groups

Publications (in chronological order last 5 years, co-author):

Year	Title	Journal
2023	Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort	Blood Cancer J
2023	Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.	Br J Haematol
2022	The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.	Front Oncol. 2022
2022	Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.	Blood Adv
2022	5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.	Eur J Haematol
2022	Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan.	Bone Marrow Transplant.
2022	Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.	Cancers (Basel)
2022	Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry.	Cancers (Basel)
2022	Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia	N Engl J Med.

2022	Use of venetoclax in patients with relapsed or refractory acute myeloid leukemia: The PETEMA Registry experience.	Cancers (Basel).
2022	European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.	Blood Adv.
2022	Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: A PETHEMA registry study.	Blood Adv.
2022	Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.	Blood Adv.
2021	Engraftment characterization of risk-stratified AML in NSGS mice.	Blood Adv.
2021	A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.	Leuk Lymphoma
2021	Characteristics, clinical outcomes and risk factors of SARS-COV-2 infection in adult acute myeloid patients: experience of the PETHEMA group.	Leuk Lymphoma
2021	Adverse prognostic impact of complex karyotype (≥ 3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL).	Leuk Res.
2021	The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the PETHEMA-FLUGAZA phase 3 clinical trial.	Cancers (Basel)
2021	A phase I trial selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients	Ann Hematol.
2021	Long-term outcomes after autologous versus allogeneic stem cell transplantation in molecularly-stratified patients with intermediate cytogenetic risk acute myeloid leukemia. A PETHEMA Study.	Transplant Cell Ther.
2021	A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.	Cancer
2021	Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.	Blood Adv
2021	Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes.	Leuk Res
2020	Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.	Br J Haematol
2020	Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols.	Eur J Haematol
2020	Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+AML.	Genes (Basel)
2019	A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.	Leuk Res.
2019	Real life outcomes of patients aged ≥ 75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.	Leuk Lymphoma
2019	Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis.	Haematologica